Altamira Therapeutics Files 2024 Annual Report
Ticker: CYTOF · Form: 20-F · Filed: Apr 30, 2025 · CIK: 1601936
Sentiment: neutral
Topics: annual-report, 20-F, pharmaceuticals
TL;DR
Altamira Therapeutics filed its 2024 20-F, check it for full year financials.
AI Summary
Altamira Therapeutics Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2024. The company, formerly known as Auris Medical Holding Ltd., is based in Hamilton, Bermuda. This filing provides a comprehensive overview of the company's operations and financial status for the reporting period.
Why It Matters
This annual report provides investors and stakeholders with a detailed look at Altamira Therapeutics' performance and financial health for the fiscal year 2024, which is crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Altamira Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024 — Fiscal Year End (The period covered by the annual report.)
- 20250430 — Filing Date (The date the 20-F was submitted to the SEC.)
Key Players & Entities
- Altamira Therapeutics Ltd. (company) — Filer of the 20-F
- Auris Medical Holding Ltd. (company) — Former name of Altamira Therapeutics Ltd.
- December 31, 2024 (date) — Fiscal year end for the report
- 20250430 (date) — Filing date of the report
FAQ
What is the primary business of Altamira Therapeutics Ltd.?
Altamira Therapeutics Ltd. is classified under the Pharmaceutical Preparations industry (SIC code 2834).
When did Altamira Therapeutics Ltd. change its name from Auris Medical Holding Ltd.?
The company changed its name from Auris Medical Holding Ltd. on March 18, 2019.
What is the SEC file number for Altamira Therapeutics Ltd.?
The SEC file number for Altamira Therapeutics Ltd. is 001-36582.
Where is Altamira Therapeutics Ltd. incorporated?
Altamira Therapeutics Ltd. is incorporated in D0.
What type of filing is this document?
This document is an annual report on Form 20-F for the fiscal year ended December 31, 2024.
Filing Details
This Form 20-F (Form 20-F) was filed with the SEC on April 30, 2025 regarding Altamira Therapeutics Ltd. (CYTOF).